Study: health of U.S. children deteriorating
A new study looking at the overall health of U.S. Children leads MedicalWatch for July 8, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Province warns of possible measles exposure at Winkler clinic, reports 14 more cases
Manitoba public health officials are warning of possible measles exposure at a medical centre in Winkler, as the province also confirmed 14 new cases since its last update. Anyone who was in the Winkler Medical Clinic, located at 344 First St. in the southern Manitoba city, last Friday from 11:45 a.m. to 2:15 p.m is asked to monitor for symptoms until July 26, the province said in a Wednesday notice. According to the province's most recent data, also updated Wednesday, there were 14 new confirmed cases between June 29 and July 5, bringing the total number of confirmed measles infections to 130 so far this year. The number of cases spiked in May, with 72 reported. A total of 28 confirmed cases were reported in June. There have also been eight probable cases since the start of the year: four reported in April and four in June. Canada achieved measles elimination status in 1998, but imported cases have resulted in outbreaks that started in New Brunswick in October. From Dec. 29 to June 28, there had been 3,703 reported measles cases in Canada, according to the latest data from Health Canada. The highly infectious disease spreads through droplets formed in the air when someone coughs, sneezes or talks. Even a few minutes in the same space as a sick person poses infection risks, as the virus can linger on surfaces for two hours after an infected person leaves. Symptoms of measles generally appear seven to 21 days after exposure, and may include a fever, runny nose, drowsiness and red eyes, Manitoba Health says. Small white spots can also appear on the inside of the mouth or throat. Immunization is the only way to protect people from contracting measles, the province says. A two-dose measles vaccine program for measles, mumps, rubella and varicella (chickenpox) is routinely provided for kids at least one year old and again at age four to six in Manitoba. If a child is exposed to measles, the province said a second dose can be given earlier. Manitoba has expanded eligibility for vaccines to infants as young as six months old living in the Southern Health region and the Interlake-Eastern Regional Health Authority area. The province also extended vaccine eligibility to start at six months for children who were evacuated from their communities because of wildfires and who may be staying in southern Manitoba, where there have been measles outbreaks.
CTV News
an hour ago
- CTV News
BREAKING: London, Ont. hospital sues former staff, contractors for $60M+ in alleged fraud and negligence
(L-R) Dipesh Patel, Neel Modi, Paresh Soni, Derek Lall, are all named in a fraud lawsuit by London Health Sciences Centre. London Health Sciences Centre (LHSC) is suing several former employees and contractors, alleging a fraudulent scheme that defrauded the hospital of tens of millions of dollars over more than a decade. In a statement of claim filed in court, LHSC is first seeking $50-million in damages, plus an additional $1.5-million in punitive damages, against former executive Dipesh Patel, Derek Lall, and Neel Modi, as well as director of BH Contractors Paresh Soni and construction firms BH Contractors and GBI Construction. The hospital alleges the group conspired to manipulate procurement processes, submit fraudulent documents, inflate invoices, and improperly award contracts to companies with undisclosed conflicts of interest, actions LHSC believes amount to civil fraud, breach of fiduciary duty, and unjust enrichment. Patel, who served as a senior executive overseeing facilities management between 2013 and 2024, is accused of being a central figure in the scheme. According to LHSC, Patel helped direct millions of dollars in contracts to companies linked to Soni, a close associate, without disclosing the conflict of interest. Patel was terminated in August 2024. Between 2015 and 2024, BH Contractors, which LHSC claims was controlled by Soni, received nearly $30-million in payments, including over $21 million for a window replacement project at University Hospital. LHSC alleges the bid for that project was irregular and non-compliant, and that BH inflated costs by about $10 million above independent estimates. In a separate instance, GBI Construction, also linked to Soni, allegedly invoiced LHSC more than $330,000 for services tied to an allegedly fictitious system. Between 2013 and 2024, LHCS alleges GBI received more than $11 million from the hospital. The hospital alleges the defendants used aliases and forged documents to secure contracts, including submitting falsified insurance and safety certifications. For example, in 2022, BH Contractors renewed its vendor-of-record status with documents allegedly signed by 'Paul Smith,' an alias LHSC says was used by Soni. The statement of claim also outlines what is believed to be suspicious real estate activity. Patel is said to have acquired or controlled at least 22 properties, 17 of which were purchased after BH won the University Hospital window contract. According to the statement of claim, Soni is linked to at least 43 properties valued at nearly $14 million, most acquired after GBI secured long-term contracts with LHSC. Modi and Lall, both former LHSC employees who reported to Patel, were also terminated — Modi for cause in February 2025 and Lall retroactively in April of the same year, due to their alleged involvement in the scheme. LHSC terminated its agreements with GBI and BH Contractors in September 2024 and June 2025, respectively. The hospital says it uncovered the alleged fraud in late 2024 during a probe into irregularities in procurement. The claim stated that full details of the alleged damages will be provided before trial but estimates current losses at approximately $50 million. The allegations have not yet been tested in court. LHSC sues ex-executives over alleged cover-up of fraud scheme In their second statement of claim, London Health Sciences Centre is also suing three former executives and a consulting firm for $10 million, alleging they ignored or concealed evidence of fraud that may have cost the hospital millions of dollars. LHSC filed a statement of claim in Ontario Superior Court, accusing former CEO Jackie Schleifer Taylor, former CFO Abhijeet Mukherjee, former executive Bradley Campbell, and consulting firm Corpus Sanchez International, of breach of fiduciary duty, negligence, and willful misconduct. The lawsuit claims the defendants failed to act after being made aware of a confidential report in 2022 that raised concerns about possible fraud in hospital procurement and construction contracts. LHSC alleges the executives didn't inform the board, internal auditors, or external audit firm Ernst & Young about the allegations. Instead, the statement claims, the accused allowed staff implicated in the report to oversee an internal cost review that made no mention of the suspected wrongdoing. The hospital further alleges that Schleifer Taylor and Mukherjee signed audit representations falsely affirming there were no known issues of fraud, in breach of professional and legal standards. The defendants are jointly and severally liable, according to the claim, and the hospital is seeking to recover employment compensation paid to them, plus $100,000 in punitive damages. None of the allegations have been proven in court, and no statements of defense have been filed.
National Post
an hour ago
- National Post
Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
Article content NATICK, Mass. — Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with Minogue Medical Inc., a leading Canadian medical device company specializing in bariatric and obesity care. This new partnership draws upon Minogue Medical's 40-year experience in the Canadian market and reflects Allurion's commitment to establishing a new standard of care in obesity management focused on metabolically healthy weight loss. Article content Minogue Medical has extensive experience in building high-performing medical networks across Canada. With a national ecosystem of dietitians, bariatric surgeons, and endoscopic specialists, the company ensures every patient journey is supported by highly qualified professionals who deliver a comprehensive program. Through its rigorous vetting and training processes, Minogue has become a trusted name in bringing advanced technologies into clinical practice. Article content Article content 'We select partners who share our vision for ethical, patient-centered care,' said Danny Minogue, CEO of Minogue Medical. 'Allurion's commitment to clinical rigor complements our approach, and together, we intend to set a new benchmark in Canadian weight management.' Article content Allurion is pioneering metabolically healthy weight loss, a new approach to obesity care focused on losing weight, keeping it off, and maintaining muscle. In partnership with Minogue Medical, Allurion will now be able to access providers who are committed to this approach and have demonstrated exceptional clinical results. In addition, the partnership is expected to increase access to providers offering a combination of the Allurion Program with GLP-1 therapy, to further enhance short and long-term results. Article content 'Minogue Medical has built a strong reputation in Canada for its deep clinical expertise, strong network, and a proven ability to bring meaningful innovations to the field of metabolic and bariatric care,' said Dr. Michel Gagner, a leading Canadian bariatric surgeon. 'Their multidisciplinary approach—engaging dietitians, surgeons, and endoscopists alike—ensures that patients are treated within a medically supervised, evidence-based framework. I am confident that this partnership represents a pivotal step forward for obesity care in Canada.' Article content 'This agreement with Minogue Medical reflects our commitment to find partners globally who believe in our approach to obesity care,' said Dr. Shantanu Gaur, Founder and CEO of Allurion. 'We are looking forward to working with Minogue to develop the Canadian market and establish a new standard of care in the treatment of obesity.' Article content About Minogue Medical Inc. Article content Minogue Medical is a Canadian medical device distributor with deep expertise in the bariatric and metabolic health space. With a focus on ethical integration, clinician training, and long-term care pathways, Minogue supports a national network of medical professionals in delivering high-quality, patient-centered care. Article content About Allurion Article content Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world's first and only swallowable, Procedureless Article content TM Article content gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States. Article content For more information about Allurion and the Allurion Virtual Care Suite, please visit Article content Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world. Article content Forward-Looking Statements Article content This press release contains forward-looking statements that reflect Allurion's beliefs and assumptions based on information currently available. In some cases, you can identify forward-looking statements by the following words: 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terms, although not all forward-looking statements contain these words. Although Allurion believes it has a reasonable basis for each forward-looking statement contained in this release, these statements involve risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Article content Forward-looking statements in this press release include, but are not limited to, statements regarding: establishing a new standard for weight loss; choosing appropriate partners; pioneering inability healthy weight loss; the uniqueness of Allurion's product and service offerings, including the Allurion Program; and other statements about future events that reflect the current beliefs and assumptions of Allurion's management based on information currently available to management. Article content Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Program, including the Allurion Balloon; the timing of, and results from, Allurion's clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Balloon; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to maintain its listing on the New York Stock Exchange; a changing regulatory landscape in the highly competitive industry in which Allurion competes; the impact of the imposition of current and potential tariffs and trade negotiations, and those factors discussed under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ('SEC') on March 27, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law. Article content Article content Article content Contacts Article content Media Article content Article content Allurion Press Office Article content Article content Article content Article content
